Google, IBM & Meta Certificates – 40% Off
One plan covers every Professional Certificate on Coursera.
Unlock All Certificates
Learn about the latest bladder cancer clinical trial results and treatment advances from the 2025 ASCO Genitourinary Cancers Symposium in this 20-minute medical education video. Discover key findings from three major clinical trials that are shaping bladder cancer treatment protocols. Explore the NIAGARA trial results showing that pre-cystectomy circulating tumor DNA (ctDNA) positivity correlates with 97% non-pathologic complete response rates, while post-cystectomy ctDNA positivity indicates high disease relapse risk. Examine the EV302 trial outcomes demonstrating that enfortumab vedotin plus pembrolizumab (EV+P) combination therapy achieved superior overall response rates of 67.6% versus 44.2% compared to standard treatment, with responders showing 49% progression-free survival and 75% overall survival at 2 years. Review the JAVELIN BLADDER trial data revealing that sacituzumab govitecan combined with avelumab significantly improved overall response rates (24% vs 3%) and median progression-free survival (hazard ratio 0.49; 95% CI 0.31-0.76). Gain insights into how these clinical developments may influence future bladder cancer management strategies and patient care decisions from genitourinary oncology specialists at Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology.
